Sorrento Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sorrento Therapeutics, Inc.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
Novartis and Roche's Xolair was approved as a treatment for hives in 2014 and has transformed treatment for patients with severe symptoms. New data on the former's new IgE inhibitor suggest that a more effective drug could be on the way.
- Specialty Pharmaceuticals
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Large Molecule
- Other Names / Subsidiaries
- SCILEX Pharmaceuticals, Inc.
- Scilex Holding Company
- Scintilla Pharmaceuticals, Inc.
- Semnur Pharmaceuticals, Inc.
- Sherrington Pharmaceuticals
- TNK Therapeutics, Inc.
- Virttu Biologics Limited